Founded in 2018, SEED Biosciences is developing a new enabling tool to make cell and gene therapy a standard of care. Through a Tech Growth loan in the amount of CHF 400’000, the Foundation for Technological Innovation (FIT) will fund SEED Biosciences’ sales distribution network expansion in the US to partner with market leaders in lab automation.
The start-up located at the Biopôle in Lausanne (canton of Vaud) provides scientists with tools that are gentle with cells, affordable, intuitive, and compliant with stringent regulatory issues. In this sense, they developed a Swiss-made award-winning product called DispenCell to enable scientists to isolate single cell lines three times faster and ten times cheaper than existing solutions.
The new pipetting robot enables scientists to isolate a single cell as easy as point and click. This tool aims to become the new standard of care. Through their innovation, SEED Biosciences ambitions to become a market leader and a door opener to personalized medicine and help find efficient treatments.
A future leader in personalized medicine
The 12-people team aims to democratize single-cell technology and easily integrate DispenCell into standard laboratory processes. This way, SEED Biosciences seeks to explore the full spectrum of possibilities its technology offers to become a leader in personalized medicine.
After 18 months since product launch, the start-up counts already twenty recurrent clients in Europe, US and Asia, such as Merck, and Sanofi as well as leading stem cell therapy companies like Century Therapeutics. In addition, it recently won the New Product Award at the SLAS2022 conference in Boston for bringing its product to market within 90 days pre-and post-conference.
For SEED Biosciences, the new funds from the FIT will allow the development of its distribution network in the US. The objective is to partner with market leaders in lab automation. The FIT loan will notably be directly involved in the building process and industrialization of the technology.
